66th ASH Annual Meeting: 905. Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies: Poster III

Symposia: Outcomes Research: Non-Malignant Conditions Excluding Hemoglobinopathies Oral and Poster Abstracts
Poster

Research, Bleeding and Clotting, Combination therapy, Adult, Clinical Practice (Health Services and Quality), Bone Marrow Failure Syndromes, Bispecific Antibody Therapy, Hemophilia, Drug development, Epidemiology, Elderly, Platelet disorders, Clinical Research, Health outcomes research, Diversity, Equity, and Inclusion (DEI), Thromboembolism, Paroxysmal Nocturnal Hemoglobinuria, Health disparities research, Education, Diseases, Immune Disorders, Thrombocytopenias, Patient-reported outcomes, Treatment Considerations, Biological therapies, Thrombotic disorders, Real-world evidence, Adverse Events, White blood cell disorders, Registries, Monoclonal Antibody Therapy, Survivorship, Study Population, Human

Halls G-H (San Diego Convention Center)

5073

Assessing the Contribution of Duffy Null Phenotype to Disparities in Eligibility Criteria for Clinical Trials for Newly-Diagnosed Colorectal Cancer

Lauren E. Merz, MD, MSc^1,2, Yating Wang, MS³^*, Elad Sharon, MD, MPH⁴^*, Thomas P Walsh⁵^*, Gregory Abel, MD, MPH⁵ and Andrew Hantel, MD⁶

¹Division of Hematology/Oncology, Mass General Brigham, Boston, MA
²Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA
³Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
⁴Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁶HMS Center for Bioethics, Dana-Farber Cancer Institute, Boston, MA

5074

Real-World Drug Adherence, Persistence, and Healthcare Resource Utilization in Patients with Paroxysmal Nocturnal Hemoglobinuria in the USA: The Advantage Study

Elizabeth A. Griffiths, MD¹, Andrew Messali²^*, Mohammed Mahdi²^*, Maral DerSarkissian³^*, Rose Chang³^*, Brendan Rabideau³^* and David Dingli, MD, PhD⁴

¹Roswell Park Comprehensive Cancer Center, Buffalo, NY
²Alexion, AstraZeneca Rare Disease, Boston, MA
³Analysis Group, Inc., Boston, MA
⁴Mayo Clinic, Rochester, MN

5075

Juliana Schwaab, MD¹^*, Paul Dolin²^*, Priya Jain², Jennifer Rowell³^*, Chris Edmonds⁴^*, Josepine Persson⁵^*, Daniel Mascia⁶^*, Tia Pennant⁶^*, Fritha Hennessy⁶^* and Stephanie Yanjing Chen⁷^*

¹Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany
²BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
³Market Access and Pricing, AstraZeneca, Cambridge, United Kingdom
⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD
⁵Market Access and Pricing, AstraZeneca, Gothenburg, Sweden
⁶Adelphi Real World, Bollington, United Kingdom
⁷BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

5076

Global Prevalence of Iron Deficiency Utilizing Differing Ferritin Cut-Offs - 15, 30, and 50 μg/L

Emma P Deloughery, MD¹ and Thomas G Deloughery, MD²

¹Oregon Health & Science University, Portland, OR
²Division of Hematology and Medical Oncology, Oregon Health and Science Univ., Portland, OR

5077

Burden of Treatment on People with Hemophilia: Global Real-World Data

Víctor Jiménez-Yuste, MD, PhD¹^*, Cléa Percier, PharmD²^*, Naveen Shridhar, MBBS, PhD³^*, Neil Reynolds⁴^*, Olivera Rajkovic-Hooley⁴^*, Thom Dewar⁴^* and Giancarlo Castaman⁵^*

¹Hospital Universitario La Paz, Universidad Autónoma de Madrid, Madrid, Spain
²Novo Nordisk Health Care AG, Zürich, Switzerland
³Novo Nordisk Service Centre India Private Limited, Bangalore, India
⁴Adelphi Real World, Bollington, United Kingdom
⁵Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy

5078

Real-World Experience with Emicizumab for Hemophilia a from the Physician Perspective Based on Survey Data

Michael Recht, MD, PhD, MBA^1,2^*, Hanna Salehi, MSc³^*, Chris Blazos, BSc⁴^*, Sophie Lai, BSc⁴^*, Ella Morton, BSc⁴^*, Lucy Lee, PharmD, MPH⁵^*, Juliana M.L. Biondo, MD⁵ and Janet S Lee⁵^*

¹National Bleeding Disorders Foundation, New York, NY
²Yale School of Medicine, New Haven, CT
³Adelphi Real World, Bollington, United Kingdom
⁴Adelphi Real World, Macclesfield, United Kingdom
⁵Genentech, Inc., South San Francisco, CA

5079

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Claire Booth, MBBS, PhD^1,2^*, Patrick Gilbert³^*, Luuk Gras⁴^*, Hawazen Alsaedi⁵^*, Amir Ali Hamidieh⁶^*, Mor Seny Gueye⁷^*, Mary Slatter, MD⁸^*, Ashrafsadat Mousavi⁹^*, Amos Toren¹⁰^*, Musa Karakukcu, MD¹¹^*, Abdelghani Tbakhi¹²^*, Polina Stepensky¹³^*, Gulyuz Ozturk¹⁴^*, Peter Bader¹⁵, Henrik Sengeloev¹⁶^*, Tayfun Güngör¹⁷^*, R.F. Wynn¹⁸^*, Franco Locatelli, MD¹⁹, Maria Chitty-Lopez, MD²⁰^*, Joana E Matos²⁰^*, Stuart Turner²⁰^*, Gayatri R Rao, MD, JD²⁰^*, Jonathan D Schwartz, MD²⁰, Michael H Albert²¹^* and Bénédicte Neven²²^*

¹University College London Great Ormond Street Institute of Child Health, London, United Kingdom
²Department of Paediatric Immunology and Gene Therapy, Great Ormond Street Hospital NHS Trust, London, United Kingdom
³EBMT Leiden Study Unit, Leiden, Netherlands
⁴EBMT, Leiden, Netherlands
⁵King Faisal Specialist Hospital and Research Centre, Riyadh, SAU
⁶Pediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of)
⁷Hospital Necker-Enfants Malades, Paris, France
⁸Paediatric Stem Cell Transplant Unit, Great North Children’s Hospital, Newcastle Upon Tyne, United Kingdom
⁹Shariati Hospital, Teheran, Iran (Islamic Republic of)
¹⁰Sheba Medical Center, Tel-Hashomer, Israel
¹¹Pediatri Hematoloji Onkoloji Başkanı, Erciyes Üniversitesi, Kayseri, Turkey
¹²King Hussein Cancer Foundation and Center, Amman, Jordan
¹³Hadassah University Hospital, Jerusalem, Israel
¹⁴Acibadem Saglik Hizmetleri ve Ticaret Anonim Sirketi, Istanbul, TUR
¹⁵Universitätsklinikum Frankfurt Goethe-Universität, Frankfurt, Germany
¹⁶Rigshospitalet, Copenhagen, Denmark
¹⁷Hematology/Oncology/Immunology, Gene Therapy, and Stem Cell Transplantation, University Children's Hospital Zurich-Eleonore Foundation & Children's Research Center, Zürich, Switzerland
¹⁸Royal Manchester Children's Hospital, Manchester, United Kingdom
¹⁹IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy
²⁰Rocket Pharmaceuticals, Inc., Cranbury, NJ
²¹Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universität München, Munich, Germany
²²Unité d'Immuno-Hématologie et Rhumatologie Pédiatrique, Assistance Publique-Hôpitaux de Paris, Paris, France

5080

Real-World Experience with Combination Therapy of Fostamatinib and Thrombopoetin Receptor Agonists (TPO-RAs) for Treatment of Immune Thrombocytopenia (ITP): Patient-Reported Outcomes

Elizabeth Bowhay-Carnes, MD¹^*, Yuliya Kreychman²^*, Lucas Buxman³^* and Leslie Todd²^*

¹Division of Hematology-Oncology, Mays Cancer Center at UT Health MD Anderson, San Antonio, TX
²Rigel Pharmaceuticals, Inc., South San Francisco, CA
³Claritas Rx, Inc., South San Francisco

5081

A Systematic Review of 72 ASH Plenary and Late Breaking Abstracts for Racial Representation: A Health Equity Call to Action

Maya Birhiray, MS^*, Sam Ranger, M.S.^* and Ruemu Birhiray

Indy Hematology Education Inc., Carmel, IN

5082

Treatment Adherence, Satisfaction and Quality of Life of Adult Patients with Severe Haemophilia a: Results from a Real-World Survey of Physicians and Patients

Valeria Merla, MPH¹^*, Sheena Thakkar, MPH¹^*, Jasmine Healy, PhD²^*, Ella Morton, BSc³^*, Kieran Wynne-Cattanach, MSc³^*, Nathan Ball, BSc³^*, Sophie Lai, BSc³^*, Chris Blazos, BSc³^* and Hanna Salehi, MSc³^*

¹Pfizer Inc, New York, NY
²Pfizer Canada ULC, Kirkland, QC, Canada
³Adelphi Real World, Bollington, United Kingdom

5083

Quality of Life, Physical and Mental Health of Patients with Vaccine Induced Immune Thrombotic Thrombocytopenia after Extended Followup

Meera Karunakaran^1,2^*, Fatema Hossain^1,2^*, Erin Jamula, MSc^1,2^*, Ishac Nazy, PhD^1,2,3 and Donald Arnold, MD^1,2

¹Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada
²Department of Medicine, McMaster University, Hamilton, ON, Canada
³Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada

5084

Comparative Venous and Arterial Thromboembolism Profiles Associated with Different Cyclin-Dependent Kinase 4/6 Inhibitors: A Real-World Study

Cho Han Chiang¹^*, Shuwen Lin, MD²^*, Yu-Cheng Chang, MD³^*, Junmin Song, MD⁴, Kuan-Yu Chi, MD⁴^*, Nutchapon Xanthavanij, MD⁵^*, Yu Chang, MD⁶^*, Cho-Hung Chiang, MD⁷^* and Xiaocao/Haze Xu, MBBS⁸^*

¹Department of Medicine, Mount Auburn Hospital, Cambridge, MA
²Montefiore Medical Center, Montefiore Einstein Cancer Center, Bronx, NY
³Department of Medicine, Danbury Hospital, Danbury, CT
⁴Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY
⁵Mount Auburn Hospital, Cambridge, MA
⁶Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
⁷National Taiwan University Hospital, Taipei, Taiwan
⁸University of Vermont Medical Center, Burlington, VT

5085

Real-World Clinical Outcomes for Complement Inhibitor Experienced and Naïve Paroxysmal Nocturnal Hemoglobinuria Patients Prescribed Pegcetacoplan in Europe and Canada

Jens Panse, MD¹, Juan Carlos Vallejo Llamas, MD²^*, Koo Wilson, MSc³^*, Zalmai Hakimi, PhD³^*, Barbara Czech, PhD³^*, Brianne Kerr, BSc⁴^*, Sam Williamson, BSc⁴^*, Jade Garratt-Wheeldon, BSc⁴^*, Yasmin Taylor, MSc, BSc⁴^*, Niall Hatchell, MSc, BSc⁴^* and Christopher Patriquin, MD, MSc, FRCPC⁵

¹Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany & Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany
²University Clinical Hospital of Santiago, Santiago De Compostela, Spain
³Swedish Orphan Biovitrum AB, Stockholm, Sweden
⁴Adelphi Real World, Bollington, United Kingdom
⁵Division of Medical Oncology & Hematology, University Health Network, Toronto, ON, Canada

5086

Clinical Outcomes of Cancer-Associated Venous Thromboembolism in Patients with Gastrointestinal or Genitourinary Cancers Treated with Direct Oral Anticoagulant Vs. Low Molecular Weight Heparin

Kristi Upadhyaya¹^*, Xiaoying Chen²^*, Alok A. Khorana, MD¹ and Dana Elizabeth Angelini, MD¹

¹Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
²Cleveland Clinic, Quantitative Health Sciences, Lerner Research Institute, Cleveland, OH

5087

Challenges in PNH and CAD Management Revealed through Educational Interventions over Three Years

Sumera Ackbarali¹^*, Tariqa Ackbarali, MSc²^*, Katie Kowalski, MPH³^*, Shirley D'Sa, FRCP FRCPath MD(Res)⁴^*, Carlos M de Castro, MD⁵, Satheesh Chonat, MD⁶ and Catherine M. Broome, MD⁷

¹PlatformQ Health Education, LLC, Lake Worth, FL
²PlatformQ Health, Lake Worth, FL
³National Organization for Rare Disorders, Danbury, CT
⁴University College London Hospitals NHS Foundation Trust, London, United Kingdom
⁵Duke University, Durham, NC
⁶Cincinnati Children's Hospital, Atlanta, GA
⁷Georgetown University Medical Center, Lombardi Comprehensive Cancer Center, Washington, DC

5088

Role of Social Determinants of Health on Infection-Related Hospitalizations in Pediatric Hematopoietic Stem Cell Transplant Patients within the First 100 Days Post-Transplant in an Underserved State

Alexis Brantley, MD¹^*, Nali Gillespie, M.D.²^*, Morgan Viviano, MD¹^*, Leah Smith, DO¹^*, Zhide Feng, PhD³^*, Maria C. Velez-Yanguas, MD⁴ and Zachary LeBlanc, MD⁵^*

¹Louisiana State University Health Sciences Center School of Medicine, New Orleans
²Louisiana State University Health Sciences Center School of Medicine, New Orleans, LA
³Department of Biostatistics, Louisiana State University Health Sciences Center, New Orleans
⁴Division of Pedatric Hematology and Oncology, Louisiana State University Health Sciences Center School of Medicine, New Orleans, LA
⁵Division of Pediatric Hematology and Oncology, Louisiana State University Health Sciences Center School of Medicine, New Orleans, LA

5089

An Evaluation of Andexanet Alfa v. Standard of Care for Reversal of Doac-Induced Intracranial Hemorrhage – a Systematic Review and Meta-Analysis

Alexander J Xiang¹^*, Sarah Sadafi, BHSc²^*, Rachael Principato³^*, Asim Shaikh, BHSc²^*, Mehrad Nowrouzi²^*, Allen Li, MD⁴, Ali Eshaghpour, MD⁵ and Mark A. Crowther, MD, MSc, FRSC, FRCPC, LLM⁵

¹Department of Medicine, McMaster University, Kitchener, ON, Canada
²McMaster University, Hamilton, Canada
³University of Guelph, Guelph, Canada
⁴Department of Vascular Surgery, University of Toronto, Toronto, ON, Canada
⁵Department of Medicine, McMaster University, Hamilton, Canada

5090

A Systematic Literature Review of Real-World Outcomes Following Anti-Interleukin-5 and Anti-Interleukin-5 Receptor Alpha Treatment for Hypereosinophilic Syndrome: Case Reports and Cohort Studies

Priya Jain¹, Jennifer Rowell²^*, Chris Edmonds³^*, Michael Stokes⁴^*, Ning Ding⁵^* and Stephanie Yanjing Chen⁶^*

¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom
²Market Access and Pricing, AstraZeneca, Cambridge, United Kingdom
³Market Access and Pricing, AstraZeneca, Gaithersburg, MD
⁴Data Analytics, Evidera, Saint-Laurent, QC, Canada
⁵Data Analytics, Evidera, Bethesda, MD
⁶BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD

5091

Association of Anticoagulant Therapy with Bleeding in Patients with Chronic Liver Disease: A Case-Cross over Study Using the National Veterans Health Administration Database

Amber Afzal, MD, MSc¹, Brian F. Gage, MD, MSc²^*, Luo Suhong³^* and Kristen M. Sanfilippo, MD^4,5

¹Washington University School of Medicine St Louis, Saint Louis, MO
²Washington University School of Medicine in St. Louis, St Louis, MO
³Veterans Health Administration, Saint Louis, MO
⁴Washington University School of Medicine St Louis, Chesterfield, MO
⁵St Louis Veterans Affairs Medical Center, Saint Louis, MO

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH